JUNO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Juno Therapeutics Inc. and a Lead Plaintiff Deadline of September 12, 2016

NEW YORK, Aug. 05, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington, Seattle Division on behalf of investors who purchased Juno Therapeutics Inc. (NASDAQ:JUNO) securities between June 4, 2016 and July 7, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/juno-therapeutics-inc. There is no cost or obligation to you.

According to the complaint, Juno allegedly materially misled investors by failing to disclose the May 2016 death of a patient in the Company’s Phase 2 trial of product candidate JCAR015.  These omissions led Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death. Then, following the death of two other patients in June and July, the U.S. Food and Drug Administration issued a clinical hold on the study, and Juno disclosed the patients’ deaths.

If you suffered a loss in Juno Therapeutics you have until September 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/juno-therapeutics-inc.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:  	
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

08/05/2016 9:00

© Copyright Globe Newswire. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire.